Daily Bulletin

The Times Real Estate

.

Yingli Pharma Announces NMPA Approval of New Anti-cancer Drug Linperlisib

The first highly selective PI3Kδ inhibitor in China

SHANGHAI, CHINA - Media OutReach - 9 November 2022 - Shanghai Yingli Pharmaceutical Co., Ltd. (the "Company" or "Yingli Pharma") is pleased to announce that linperlisib, trade name因他瑞®, a novel phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, has been approved by the National Medical Products Administration (NMPA) of China on November 9 for the treatment of relapsed/refractory follicular lymphoma (R/R FL) in patients who have received 2 or more prior systemic therapies.

Business News

How to Estimate the Right Skip Bin Size for Your Renovation Project

One of the most challenging aspects of planning a renovation project is estimating the amount of waste you'll generate. Choosing a skip bin that's too small means paying for additional bins or picku...

Daily Bulletin - avatar Daily Bulletin

Cool Room Hire: The Ultimate Solution for Temperature-Sensitive Storage

Businesses in the food, pharmaceutical, and event industries often require reliable refrigeration to keep products fresh and safe. Cool room hire provides a flexible and cost-effective solution for ...

Daily Bulletin - avatar Daily Bulletin

Thryv Australia named global winner of the 2025 Microsoft Advertising Partner Awards

Melbourne – 11 March 2025:   Thryv® (NASDAQ: THRY), provider of the leading small business marketing and sales software platform, has been named the global winner of the Microsoft Advertising Part...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals